 AstraZeneca PLC LON:AZN is facing rejection from the US drug regulator for its application for a novel new drug to treat anaemia resulting from chronic kidney disease. The Food and Drug Administrations FDA Cardiovascular and Renal Drugs Advisory Committee voted against approving Roxadustat on the basis of its benefit-risk profile for both non-dialysis dependent and dialysis-dependent adult patients. 